Differentiate between a migraine headache and cluster headaches. Manifestations and/or risk factors for a patient with cluster headaches include what? (Select all that apply)

First-generation antipsychotics (FGAs), also known as typical antipsychotics, are classified based on potency into low, medium, and high potency groups. High-potency agents primarily block dopamine D2 receptors and are very effective for controlling psychotic symptoms but have a higher risk of extrapyramidal side effects (EPS). They are commonly used in acute psychosis and schizophrenia management. Understanding potency classification helps predict side effects and guide safe medication selection.

Rationale:
A. Chlorpromazine (Thorazine and Largactil) is a low-potency first-generation antipsychotic. It has strong sedative and anticholinergic effects but weaker dopamine blockade compared to high-potency agents. Because of this, it causes more hypotension and sedation but fewer extrapyramidal symptoms than high-potency drugs.

B. Olanzapine (Zyprexa) is a second-generation (atypical) antipsychotic, not a first-generation drug. It has a lower risk of extrapyramidal symptoms but a higher risk of metabolic side effects such as weight gain, hyperglycemia, and dyslipidemia. Therefore, it is not classified within FGA potency groups.

C. Haloperidol (Haldol) is a high-potency first-generation antipsychotic that strongly blocks dopamine D2 receptors. It is commonly used for acute psychosis, agitation, and schizophrenia. Due to its potency, it has a higher risk of extrapyramidal side effects such as dystonia, parkinsonism, and tardive dyskinesia.

D. Aripiprazole (Abilify) is a second-generation antipsychotic that acts as a partial dopamine agonist. It is not part of the first-generation classification and therefore does not fall into low, medium, or high potency FGA categories. It is associated with a lower risk of extrapyramidal symptoms compared to typical antipsychotics.

Management of Bipolar disorder often requires combination pharmacotherapy to address both acute symptoms and long-term stabilization. Lithium is effective for maintenance therapy and prevention of mood episodes, but additional medications may be needed during acute exacerbations. Risperidone is commonly added to control acute manic symptoms such as agitation, psychosis, and behavioral dysregulation. Combination therapy enhances symptom control and improves patient stability.

Rationale:
A. Elevating mood during depressive episodes is not the primary role of risperidone. While some atypical antipsychotics have antidepressant effects, risperidone is mainly used for controlling psychosis and mania. Mood elevation in depression is managed with antidepressants or mood stabilizers rather than this medication.

B. Preventing recurrence of depressive episodes is primarily achieved with mood stabilizers like lithium. Although some antipsychotics may contribute to mood stabilization, risperidone is not specifically indicated for preventing depressive relapses. Its main benefit lies in acute symptom control rather than long-term prevention of depression.

C. Managing tremors associated with lithium use is not an indication for risperidone. Lithium-induced tremors are usually managed by dose adjustment or medications such as beta-blockers. Adding an antipsychotic would not address this side effect and may introduce additional adverse effects.

D. Helping control symptoms during manic episodes is the correct rationale for adding risperidone. It works by blocking dopamine and serotonin receptors, reducing agitation, hallucinations, and impulsivity seen in mania. This makes it effective as an adjunct to lithium in managing acute manic phases.